By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
The News God
  • Politics
  • News
  • Business & Finance
  • Lifestyle & Health
  • Law
  • Sports
  • Tech & Autos
  • Home & Garden
  • More
    • Travel
    • Education
    • Entertainment
    • General
Reading: Roche Experiences a Setback in Alzheimer’s Therapy
Share
Aa
The News God
Aa
  • Politics
  • News
  • Business & Finance
  • Lifestyle & Health
  • Law
  • Sports
  • Tech & Autos
  • Home & Garden
  • More
Search
  • Politics
  • News
  • Business & Finance
  • Lifestyle & Health
  • Law
  • Sports
  • Tech & Autos
  • Home & Garden
  • More
    • Travel
    • Education
    • Entertainment
    • General
Follow US
  • Why You Need to Read Business News Everyday
  • Why You Need to Read Business News Everyday
  • Advertise
  • Advertise
The News God > Blog > News > Roche Experiences a Setback in Alzheimer’s Therapy
News

Roche Experiences a Setback in Alzheimer’s Therapy

Torffic Frimpong
Last updated: 2022/06/16 at 11:02 AM
Torffic Frimpong  - Content Writer Published June 16, 2022
Share
3 Min Read
SHARE

In the wake of Roche’s recent failure with the cancer medication tiragolumab, the company announced on Thursday that its Alzheimer’s drug crenezumab was unable to halt or prevent cognitive decline in patients who possessed a particular genetic mutation that leads to the disease’s onset at an earlier age. This information was gleaned from research.

According to a statement released by the pharmaceutical company that makes Crenezumab, the drug’s co-primary objectives of assessing cognitive capacity and episodic memory function did not reveal statistically relevant therapeutic improvements.

Roche decided to conduct the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease (ADAD) Colombia Trial to determine whether or not crenezumab can slow the progression of Alzheimer’s disease or even prevent it entirely in cognitively normal individuals who carry a particular genetic mutation.

The Basel-based business had previously encountered a significant obstacle with an unproven treatment for cancer that was being evaluated during the month before this one.

In the wake of Roche’s recent failure with the cancer medication tiragolumab, the company announced on Thursday that its Alzheimer’s drug crenezumab was unable to halt or prevent cognitive decline in patients who possessed a particular genetic mutation that leads to the disease’s onset at an earlier age. This information was gleaned from research.

According to a statement released by the pharmaceutical company that makes Crenezumab, the drug’s co-primary objectives of assessing cognitive capacity and episodic memory function did not reveal statistically relevant therapeutic improvements.

Roche decided to conduct the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer’s Disease (ADAD) Colombia Trial to determine whether or not crenezumab can slow the progression of Alzheimer’s disease or even prevent it entirely in cognitively normal individuals who carry a particular genetic mutation.

The Basel-based business had previously encountered a significant obstacle with an unproven treatment for cancer that was being evaluated during the month before this one.

An interim analysis of an ongoing clinical trial that was released in May found that the investigational medication TIRAGOLUMAB, which is manufactured by Roche, did not reduce the progression of disease in newly diagnosed patients with advanced non-small-cell lung cancer (NSCLC) in combination with Roche’s authorized PD-L1 immunotherapy Tecentriq. This information was gleaned from the ongoing trial.

You Might Also Like

OpenAI Confirms ChatGPT Leak of Conversation Histories

Oklahoma man solicited toddler sex after meeting mom: Police

Houston father charged with murdering 2-year-old daughter after chase, standoff

California city pays $750K for police painting swastika.

Is Twitter Over? A Look At The State Of Twitter In 2023

Torffic Frimpong June 16, 2022
Share this Article
Facebook Twitter Email Print
Share
Previous Article Chelsea Premier League fixtures 2022/2023:Key dates and Kick offtime. Chelsea Premier League fixtures 2022/2023:Key dates and Kick offtime.
Next Article Worker Compensation: How To Know If You Need To Hire A Lawyer Worker Compensation: How To Know If You Need To Hire A Lawyer
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stay Connected

235.3k Followers Like
69.1k Followers Follow
11.6k Followers Pin
56.4k Followers Follow
136k Subscribers Subscribe

Ads

Latest News

From Start to Finish: What to Expect When Working with an Interior Designer Mover in NYC
Home and Garden March 24, 2023
How Professional IT Can Advance Your Business
Top Cloud Storage Methods for Photo Storage in 2023
Tech & Autos March 24, 2023
Beginner's Guide to Blockchain Technology
The use of blockchain and cyber security issues
Tech & Autos March 24, 2023
Why building a financial model for your eCommerce startup is important?
Why building a financial model for your eCommerce startup is important?
Business & Finance March 24, 2023

You Might also Like

OpenAI Confirms ChatGPT Leak of Conversation Histories
News

OpenAI Confirms ChatGPT Leak of Conversation Histories

March 23, 2023
News

Oklahoma man solicited toddler sex after meeting mom: Police

March 22, 2023
News

Houston father charged with murdering 2-year-old daughter after chase, standoff

March 21, 2023
News

California city pays $750K for police painting swastika.

March 21, 2023
Show More

© 2022 Thenewsgod. All Rights Reserved.

  • About
  • Contact Us
  • Terms of Use & Privacy Policy
  • Advertise
  • Disclaimer

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?